Low-dose ketamine effectiveness in acute coronary syndrome

: Low-dose ketamine effectiveness in acute coronary syndrome with opioid unresponsive or hemodynamically unstable patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190611043864N1

Enrollment

140

Registered

2020-12-30

Start date

2020-09-14

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome. Ischaemic heart diseases

Interventions

Intervention 1: Intervention group: A group of patients receiving low-dose ketamine as part of treatment (0.1-0.3 mg / kg). Intervention 2: Control group: A group of patients who do not receive low-

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: -Age above 18 years old -Age below 65 years old -Satisfaction for participating in study -Patients with acute coronary syndrome that has VAS more or equal to 9 and unstable haemodynamic (Systolic blood pressure less than or equal to 90 mm Hg or diastolic blood pressure less than or equal to 60 mm Hg or both) -Lack of precedent of sensitiveness to ketamine

Exclusion criteria

Exclusion criteria: -Dissatisfaction for participating in study -Age below than 18 years old -Age above than 65 years old -Weight below than 40 Kg -Drug or alcohol intoxication -Active psychiatric disorder -Heart rate more than 100 per minute

Design outcomes

Primary

Measure	Time frame
Heart rate. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: physical examination.;Systolic blood pressure. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: sphygmomanometer cuff based on millimeter of Hg.;Diastolic blood pressure. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: sphygmomanometer cuff based on millimeter of Hg.;Drowsiness. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: History and physical examination.;Vertigo. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: History and physical examination.;Fatigue. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: History and physical examination.;Headache. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: History and physical examination.;Pain. Timepoint: 0-15 minutes -30 minutes -45 minutes. Method of measurement: 10-visual analogue scale (VAS) - by the patient.;The amount of pethidine consumed. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: Based on milligram of drug used. observe and record files.;Confusion. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: History and physical examination.	—

Measure

Time frame

Heart rate. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: physical examination.;Systolic blood pressure. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: sphygmomanometer cuff based on millimeter of Hg.;Diastolic blood pressure. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: sphygmomanometer cuff based on millimeter of Hg.;Drowsiness. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: History and physical examination.;Vertigo. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: History and physical examination.;Fatigue. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: History and physical examination.;Headache. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: History and physical examination.;Pain. Timepoint: 0-15 minutes -30 minutes -45 minutes. Method of measurement: 10-visual analogue scale (VAS) - by the patient.;The amount of pethidine consumed. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: Based on milligram of drug used. observe and record files.;Confusion. Timepoint: 0, 15, 30, 45 minutes. Method of measurement: History and physical examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehdi Rezaei Kojani

Karaj University of Medical Sciences

rezaei.mehdi.md@gmail.com+98 26 3455 2001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026